Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Phase 2 Interventional

Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia

ClinicalTrials.gov ID: NCT07365462

Public ClinicalTrials.gov record NCT07365462. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 8:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NBI-1065890 in Adult Participants With Tardive Dyskinesia

Study identification

NCT ID
NCT07365462
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Neurocrine Biosciences
Industry
Enrollment
100 participants

Conditions and interventions

Interventions

  • NBI-1065890 Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 5, 2026
Primary completion
Jan 31, 2027
Completion
Feb 28, 2027
Last update posted
Jun 22, 2026

2026 – 2027

United States locations

U.S. sites
18
U.S. states
7
U.S. cities
18
Facility City State ZIP Site status
Neurocrine Clinical Site Bryant Arkansas 72022 Recruiting
Neurocrine Clinical Site Chino California 91710 Recruiting
Neurocrine Clinical Site Fountain Valley California 92708 Recruiting
Neurocrine Clinical Site Huntington Beach California 92648 Recruiting
Neurocrine Clinical Site Long Beach California 90807 Recruiting
Neurocrine Clinical Site Temecula California 92591 Recruiting
Neurocrine Clinical Site Torrance California 90501 Recruiting
Neurocrine Clinical Site Boca Raton Florida 33486 Recruiting
Neurocrine Clinical Site Bonita Springs Florida 34134 Recruiting
Neurocrine Clinical Site Hialeah Florida 33012 Recruiting
Neurocrine Clinical Site Miami Florida 33176 Recruiting
Neurocrine Clinical Site Orange City Florida 32763 Recruiting
Neurocrine Clinical Site Tampa Florida 33629 Recruiting
Neurocrine Clinical Site Marietta Georgia 30060 Recruiting
Neurocrine Clinical Site Lincoln Nebraska 68526 Recruiting
Neurocrine Clinical Site Beachwood Ohio 44122 Recruiting
Neurocrine Clinical Site Fort Worth Texas 76104 Recruiting
Neurocrine Clinical Site Houston Texas 77030 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07365462, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 22, 2026 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07365462 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →